Hikma Pharmaceuticals USA Inc. Sustainability Profile
Hikma Pharmaceuticals USA Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1978, Hikma has established itself as a leader in the development and manufacturing of generic and branded medications, with a strong focus on injectable products. The company operates extensively across North America, Europe, and the Middle East, providing essential healthcare solutions. Hikma's core offerings include a diverse range of injectable medicines, oral solids, and complex generics, distinguished by their commitment to quality and innovation. With a robust pipeline and a reputation for reliability, Hikma has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Recognised for its dedication to patient care, Hikma Pharmaceuticals continues to make strides in enhancing access to vital medications worldwide.
DitchCarbon Score
How does Hikma Pharmaceuticals USA Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals USA Inc.'s score of 48 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharmaceuticals USA Inc. currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Hikma Pharmaceuticals PLC, which may influence its climate commitments and performance metrics. As part of its corporate family, Hikma Pharmaceuticals USA Inc. inherits climate-related initiatives and performance data from Hikma Pharmaceuticals PLC, which is at cascade level 2. However, there are no documented reduction targets or specific climate pledges available for the US subsidiary. In the broader context, Hikma Pharmaceuticals PLC may engage in various sustainability initiatives, but specific details regarding emissions reductions or commitments at the subsidiary level remain unspecified. The absence of reported emissions data highlights a potential area for improvement in transparency and accountability regarding climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | - | - | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Hikma Pharmaceuticals USA Inc.'s Industry?
How Carbon Intensive is Hikma Pharmaceuticals USA Inc.'s Location?
Hikma Pharmaceuticals USA Inc.'s Scope 3 Categories Breakdown
Hikma Pharmaceuticals USA Inc.'s Scope 3 emissions, which decreased by 95% last year and decreased by approximately 94% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 1599% of Scope 3 emissions.
Top Scope 3 Categories
Hikma Pharmaceuticals USA Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hikma Pharmaceuticals USA Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
